Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.87-5.15%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Larimar is a clinical-stage biotech focused on rare diseases. It recently beat earnings in May 2026 and guided for about $200 million in revenue for 2026. The company has stable management and is advancing its pipeline. If it can reach this revenue target, it may prove its business model.
Larimar is loss-making with no clear profit path. It has missed earnings multiple times in 2025 and early 2026. The company relies on equity and debt raises, which dilute shareholders. Its revenue and earnings remain negative with no near-term profitability.
The market is selling off Larimar shares sharply, reflecting elevated risk and uncertainty. There is no clear consensus revenue growth or fair value priced in. Our view differs as we see the company still in a weak turnaround phase with speculative prospects.
Breaks if: cash falls below $50 million before FY27
Breaks if: EPS loss worsens or remains flat beyond FY27
revenue falls below $150 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is mixed, with management making progress on key priorities but facing challenges in a loss-making environment.
The market appears to have priced in a neutral outlook, as recent financial performance has been in the top half of its industry. However, there is an expectation of volatility due to the company's loss-making status and elevated risk profile.
Management is focused on completing a rolling submission for accelerated approval and launching a new product in 2027. Recent earnings beats indicate some positive momentum, but the overall financial performance remains neutral.
The long-term thesis hinges on management's ability to execute on their priorities and the broader healthcare sector's performance. Key triggers include guidance changes and the health of the jobs market, which could impact sentiment and estimates.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
No, our read on the company is unchanged. The risk label changed from "elevated" to "high." Recent financial performance remains steady, holding in the top half of its industry. The reason to own it still holds.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, LRMR's performance will depend on execution and external market conditions. Not investment advice.